Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Mirtazapine

FDA-approved product (tablet, oral), marketed as Mirtazapine, Remeron, Remeron Soltab.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Mirtazapine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Depressive disorder
  • Insomnia
  • Major depressive disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antidepressants
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA38.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli38.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Mirtazapine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Mirtazapine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Comparing Acupuncture With Medication to Reduce Depression, Anxiety and Comorbid Sleep Disorders in China

    NCT07552246 · start 2026-04-01

    Registered record
    Registry ID
    NCT07552246
    Conditions
    Anxiety Depression; Sleep
    Interventions
    Psychotropic Drugs; Acupuncture
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-04-01
    Completion
    2027-12-31
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnxiety Depression; Sleep
    InterventionPsychotropic Drugs; Acupuncture
    PhasePhase 4
    Registry statusRecruiting

  • Repurposing Mirtazapine in Rett Syndrome

    NCT07430046 · start 2025-07-09

    Registered record
    Registry ID
    NCT07430046
    Conditions
    RETT Syndrome With Proven MECP2 Mutation
    Interventions
    mirtazapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-07-09
    Completion
    2026-12-31
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRETT Syndrome With Proven MECP2 Mutation
    Interventionmirtazapine
    PhasePhase 2
    Registry statusRecruiting

  • Novel Pilot Study to Treat Symptoms of IBS With Diarrhea Using Combination Therapy of a Low-FODMAP Diet and a Neuromodulator

    NCT06684470 · start 2024-12-19

    Registered record
    Registry ID
    NCT06684470
    Conditions
    IBS - Irritable Bowel Syndrome; Diarrhea
    Interventions
    Mirtazapine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Recruiting
    Start
    2024-12-19
    Completion
    2026-12-19
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIBS - Irritable Bowel Syndrome; Diarrhea
    InterventionMirtazapine; Placebo
    PhaseEarly phase 1
    Registry statusRecruiting

  • Mirtazapine for the Treatment of Methamphetamine Use in Opioid Use Disorder Patients Receiving Medication Assisted Treatment

    NCT06323837 · start 2024-06-17

    Registered record
    Registry ID
    NCT06323837
    Conditions
    Stimulant Use Disorder
    Interventions
    Mirtazapine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-06-17
    Completion
    2026-12-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStimulant Use Disorder
    InterventionMirtazapine; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • Trial of Mirtazapine for Depression in IBD

    NCT06309472 · start 2024-05-07

    Registered record
    Registry ID
    NCT06309472
    Conditions
    Major Depressive Disorder; Inflammatory Bowel Diseases
    Interventions
    Mirtazapine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2024-05-07
    Completion
    2025-11-03
    Enrolment
    76

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder; Inflammatory Bowel Diseases
    InterventionMirtazapine; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Efficacy of Hydroxyzine for Patients With Panic Disorder

    NCT05737511 · start 2023-12-30

    Registered record
    Registry ID
    NCT05737511
    Conditions
    Panic Disorder
    Interventions
    Hydroxyzine; Escitalopram Oxalate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2023-12-30
    Completion
    2026-12-30
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPanic Disorder
    InterventionHydroxyzine; Escitalopram Oxalate
    PhasePhase 4
    Registry statusNot yet recruiting

  • Efficacy of Mirtazapine in Major Depressive Disorder With Insomnia

    NCT05978219 · start 2023-05-25

    Registered record
    Registry ID
    NCT05978219
    Conditions
    Major Depressive Disorder With Insomnia
    Interventions
    Mirtazapine Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2023-05-25
    Completion
    2024-03-01
    Enrolment
    135

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder With Insomnia
    InterventionMirtazapine Tablets
    PhasePhase 4
    Registry statusCompleted

  • Prophylactic Mirtazapine and Different Doses of Intrathecal Morphine in Preventing Nausea and Vomiting After Cesarean Section

    NCT06681805 · start 2023-01-01

    Registered record
    Registry ID
    NCT06681805
    Conditions
    Prophylactic; Mirtazapine; Intrathecal; Morphine; Nausea; Vomiting
    Interventions
    Mirtazapine + Bupivacaine + Morphine; Mirtazapine + Bupivacaine + Morphine; Placebo + Bupivacaine + Morphine; Placebo+ Bupivacaine + Morphine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2023-01-01
    Completion
    2024-09-25
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProphylactic; Mirtazapine; Intrathecal; Morphine +2 more
    InterventionMirtazapine + Bupivacaine + Morphine; Mirtazapine + Bupivacaine + Morphine; Placebo + Bupivacaine + Morphine; Placebo+ Bupivacaine + Morphine
    PhaseNot applicable
    Registry statusCompleted

  • Mirtazapine for Chronic Insomnia in Older Adults

    NCT05247697 · start 2022-10-01

    Registered record
    Registry ID
    NCT05247697
    Conditions
    Chronic Insomnia
    Interventions
    Mirtazapine 7.5 MG Oral Tablet once daily at bedtime; Placebo oral tablet once daily at bedtime
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-10-01
    Completion
    2024-07-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Insomnia
    InterventionMirtazapine 7.5 MG Oral Tablet once daily at bedtime; Placebo oral tablet once daily at bedtime
    PhasePhase 1
    Registry statusCompleted

  • Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder

    NCT05952713 · start 2022-10-01

    Registered record
    Registry ID
    NCT05952713
    Conditions
    Major Depressive Disorder
    Interventions
    Antidepressant
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-10-01
    Completion
    2023-07-01
    Enrolment
    73,336

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionAntidepressant
    PhaseNot recorded
    Registry statusCompleted

  • Psychopharmacotherapy for Depressive Patients

    NCT06054321 · start 2022-08-03

    Registered record
    Registry ID
    NCT06054321
    Conditions
    Major Depressive Disorder
    Interventions
    stepwise pharmacotherapy; antidepressant monotherapy group
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2022-08-03
    Completion
    2030-12-31
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    Interventionstepwise pharmacotherapy; antidepressant monotherapy group
    PhaseNot applicable
    Registry statusRecruiting

  • Elucidating Mechanisms That Underlie the Symptomatology of Functional Dyspepsia Using Novel Techniques and Its Therapeutic Validation Using Neuromodulators

    NCT06213948 · start 2021-08-01

    Registered record
    Registry ID
    NCT06213948
    Conditions
    Functional Disorder of Stomach; Healthy
    Interventions
    Mirtazapine 15 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2021-08-01
    Completion
    2025-12-31
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFunctional Disorder of Stomach; Healthy
    InterventionMirtazapine 15 MG
    PhasePhase 1
    Registry statusUnknown

  • Treating Negative Affect in Low Back Pain Patients

    NCT04747314 · start 2021-03-31

    Registered record
    Registry ID
    NCT04747314
    Conditions
    Chronic Low Back Pain; Negative Affectivity
    Interventions
    Antidepressant; Enhanced Fear Avoidance Rehabilitation
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-03-31
    Completion
    2024-12-20
    Enrolment
    308

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Low Back Pain; Negative Affectivity
    InterventionAntidepressant; Enhanced Fear Avoidance Rehabilitation
    PhasePhase 2
    Registry statusCompleted

  • Nutrition and Pharmacological Algorithm for Oncology Patients Study

    NCT04155008 · start 2021-03-01

    Registered record
    Registry ID
    NCT04155008
    Conditions
    Oncologic Complications; Quality of Life; Nutrition Poor; Head and Neck Cancer; Lung Cancer; Pancreatic Cancer
    Interventions
    Dexamethasone; Dronabinol; Mirtazapine; Nutrition Intervention
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2021-03-01
    Completion
    2021-04-05
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOncologic Complications; Quality of Life; Nutrition Poor; Head and Neck Cancer +2 more
    InterventionDexamethasone; Dronabinol; Mirtazapine; Nutrition Intervention
    PhasePhase 4
    Registry statusTerminated

  • Effects of Aprepitant/Dexamethasone Versus Mertazepine /Dexamethasone on Postoperative Nausea and Vomiting

    NCT04013386 · start 2019-07-15

    Registered record
    Registry ID
    NCT04013386
    Conditions
    Nausea and Vomiting, Postoperative
    Interventions
    Aprepitant and Dexamethasone; Mirtazapine and Dexamethasone; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-07-15
    Completion
    2019-12-31
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNausea and Vomiting, Postoperative
    InterventionAprepitant and Dexamethasone; Mirtazapine and Dexamethasone; Dexamethasone
    PhasePhase 4
    Registry statusCompleted